Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antibody coated stent a breakthrough in cardiovascular treatment

22.05.2003


An innovative medical discovery that has the potential to vastly improve the lives of people suffering from coronary artery disease was implanted today in the first human patient. The antibody coated stent, developed by Dr. Michael Kutryk, a cardiologist and clinician scientist with St. Michael’s Hospital and assistant professor, University of Toronto, was implanted into the first human patient at Thoraxcenter, University Hospital Rotterdam in Holland. The procedure was transmitted via a live feed to the EuroPCR Conference in Paris, France - a conference of over 10,000 interventional cardiologists.



Stents are wire mesh tubes that have been used for years in interventional cardiology to clear blocked arteries and to improve the flow of blood to the heart muscle. However, traditional stents have been known to cause restenosis (re-narrowing of the artery in a treated area) and can lead to blood clots. Kutryk’s invention of the antibody coated stent reduces restenosis and prevents blood clots from occurring.

"This is a very exciting time to be working in the field of interventional cardiology," says Dr. Kutryk. "When animal trials showed that antibody coated stents were successful in promoting healing and preventing restenosis, we knew this could potentially impact a large number of patients suffering from coronary artery disease."


"If the implantation of the coated stent works in humans like it has in animals, it will be one of the biggest advances in cardiology we have seen to date," says Dr. Patrick Serruys, cardiologist, University Hospital Rotterdam. "We have been calling Dr. Kutryk’s research a glimpse into the future. Today, that future is here."

When placed into a blocked area of an artery, the antibody coated stent captures endothelial progenitor cells (EPC) circulating throughout the blood. Endothelial cells are cells which line blood vessels, allowing blood to flow smoothly.

The EPCs adhere to the hard surface of the stent forming a smooth layer that not only promotes healing but prevents restenosis (re-narrowing of the artery) and blood clots, complications previously associated with the use of stents.

"We are expecting to perform the first operation of a stent on a North American patient at St. Michael’s Hospital sometime in early June," said Kutryk. "Once we determine the effectiveness of using the antibody coated stents, we will be examining other ways that this discovery can be used to improve clinical outcomes for patients suffering from cardiovascular disease. The implications are enormous."

In addition to improving outcomes for patients requiring stents, there are also implications for patients requiring cardiovascular bypass surgery. For example, a prosthetic vascular conduit (artificial artery) coated with anti-EPC antibodies would eliminate the need to use arteries from patients legs or arms for bypass surgery grafts. This would reduce surgery and anesthesia times which in turn will reduce coronary surgery deaths.

According to the Heart and Stroke Foundation of Canada cardiovascular disease accounted for 78,942 Canadian deaths in 1999 with 54 per cent of cardiovascular deaths from coronary artery disease and an additional 10 per cent of deaths from high blood pressure and hardening of the arteries.

Dr. Kutryk’s research is supported by a grant from ORBUS medical technologies. The company contributed funding the research, but had no input or influence over the research or conduct.

St. Michael’s Hospital is a Catholic teaching and research hospital, fully affiliated with the University of Toronto, specializing in heart and vascular disease, inner city health, trauma/neurosurgery, diabetes comprehensive care, minimal access therapeutics, and neurological and musculoskeletal disorders.


For more information please contact:

Tracy MacIsaac, Media Relations
St. Michael’s Hospital
Telephone: 416-864-5047
Pager: 416-864-5431

Jessica Villanueva, Media Relations
St. Michael’s Hospital
Telephone: 416-864-5034
Pager: 416-864-5431

Tracy MacIsaac | EurekAlert!
Further information:
http://www.utoronto.ca/

More articles from Health and Medicine:

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

nachricht Flexible sensors can detect movement in GI tract
11.10.2017 | Massachusetts Institute of Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Ocean atmosphere rife with microbes

17.10.2017 | Life Sciences

Neutrons observe vitamin B6-dependent enzyme activity useful for drug development

17.10.2017 | Life Sciences

NASA finds newly formed tropical storm lan over open waters

17.10.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>